<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00376090</url>
  </required_header>
  <id_info>
    <org_study_id>RV 158</org_study_id>
    <secondary_id>A-12403</secondary_id>
    <secondary_id>WRAIR 1143</secondary_id>
    <nct_id>NCT00376090</nct_id>
  </id_info>
  <brief_title>Safety of and Immune Response to a Modified Vaccinia Ankara (MVA) HIV Vaccine in HIV Uninfected Adults</brief_title>
  <official_title>A Phase I Double-Blind, Randomized, Dose Escalating, Placebo-Controlled, Study of Safety and Immunogenicity of WRAIR/NIH Live Recombinant MVA-CMDR (HIV-1 CM235 Env/ CM240 Gag/Pol) Administered by Intramuscular (IM) or Intradermal (ID) Route In HIV-Uninfected Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>U.S. Army Medical Research and Development Command</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>U.S. Army Medical Research and Development Command</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and the immune responses to the HIV&#xD;
      vaccine candidate, MVA-CMDR. This vaccine was designed to induce immune responses to three&#xD;
      HIV &quot;passenger&quot; genes encoded with the viral vector, MVA.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2005</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability</measure>
    <time_frame>Study Day 0 through 8 months post-vaccination</time_frame>
    <description>Evaluate the safety and tolerability of MVA-CMDR (HIV-1 CM235 Env/CM240 Gag/Pol) administered by IM or ID injection to HIV uninfected adults</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>Study Day 0 through Study Day 280</time_frame>
    <description>Evaluate the ability of MVA-CMDR (HIV-1 CM235 Env/CM240 Gag/Pol) to induce HIV antigen specific cellular and humoral immune responses</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Group I Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group I Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group III Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group III Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group IV Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group IV Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MVA-CMDR</intervention_name>
    <description>10^7 PFU IM, 1.0 mL</description>
    <arm_group_label>Group I Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1.0 mL IM</description>
    <arm_group_label>Group I Placebo</arm_group_label>
    <arm_group_label>Group III Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MVA-CMDR</intervention_name>
    <description>10^6 PFU ID, 0.1 mL</description>
    <arm_group_label>Group II Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0.1 mL ID</description>
    <arm_group_label>Group II Placebo</arm_group_label>
    <arm_group_label>Group IV Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MVA-CMDR</intervention_name>
    <description>10^8 PFU IM, 1.0 mL</description>
    <arm_group_label>Group III Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MVA-CMDR</intervention_name>
    <description>10^7 PFD ID, 0.1 mL</description>
    <arm_group_label>Group IV Vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        A participant must meet all of the following criteria:&#xD;
&#xD;
          -  Low risk for HIV infection&#xD;
&#xD;
          -  18 to 40 years at the time of enrollment and vaccinia naive&#xD;
&#xD;
          -  Good health&#xD;
&#xD;
          -  Availability for 12 months of participation.&#xD;
&#xD;
          -  Successful completion of the Test of Understanding&#xD;
&#xD;
          -  Able and willing to give informed consent.&#xD;
&#xD;
          -  HEMATOCRIT: WOMEN: 35 %-45 %; MEN 36 % - 49 %&#xD;
&#xD;
          -  White cell count: 3,000 - 11,000 cells/mm3&#xD;
&#xD;
          -  Platelets: 125,000 - 450,000 per mm3&#xD;
&#xD;
          -  Normal cardiac enzyme level at second Screening Visit&#xD;
&#xD;
          -  Urinalysis (UA) for protein and blood: negative or trace.&#xD;
&#xD;
          -  Normal liver function tests to include ALT/AST, alkaline phosphatase, GGT (&lt; 1.25x&#xD;
             institutional upper limits of normal) and CPK (&lt; 480) and creatinine (&lt; 1.25 mg/dL)&#xD;
&#xD;
          -  Negative serology for HIV infection&#xD;
&#xD;
          -  Any female volunteer must have a negative serum or urine pregnancy test at the&#xD;
             screening visit as well as immediately prior to each vaccine/placebo vaccination, as&#xD;
             well as verbal assurance that adequate birth control measures have been followed for&#xD;
             60 days prior to the first vaccine/placebo vaccination and will continue to be&#xD;
             followed for at least 3months after the final vaccine/placebo vaccination. This means&#xD;
             using any of the following methods: Birth control drugs that prevent pregnancy given&#xD;
             by pills, shots or placed under the skin, Male or female condoms with or without a&#xD;
             cream or gel that kills sperm, diaphragm or cervical cap with a cream or gel that&#xD;
             kills sperm, or Abstinence&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        A volunteer will be excluded if one or more of the following conditions apply.&#xD;
&#xD;
        A woman who:&#xD;
&#xD;
          -  Is pregnant.&#xD;
&#xD;
          -  Is breast-feeding.&#xD;
&#xD;
        Anyone who:&#xD;
&#xD;
          -  Is U.S. military personnel.&#xD;
&#xD;
          -  Acknowledges engaging in highest-risk behavior within six months of study entry&#xD;
&#xD;
          -  Has active tuberculosis or other systemic infectious process by review of systems and&#xD;
             physical examination.&#xD;
&#xD;
          -  Has history of or known cardiac disease including any of the following: prior&#xD;
             myocardial infarction (heart attack), angina pectoris, congestive heart failure,&#xD;
             conduction disturbances, repolarization (ST segment or T wave) abnormalities, serious&#xD;
             cardiac arrhythmias (ventricular tachycardia or ventricular fibrillation),&#xD;
             cardiomyopathy, pericarditis, stroke or transient ischemic attack, chest pain or&#xD;
             shortness of breath with activity (e.g. climbing stairs), valvular heart disease&#xD;
             including mitral valve prolapse, or other heart conditions under the care of a doctor.&#xD;
&#xD;
          -  Has ECG on Screening Visit 2 with clinical significant findings, or features that&#xD;
             would interfere with the assessment of myo/pericarditis (as determined by the contract&#xD;
             ECG Lab) including any of the following: conduction disturbance (atrioventricular or&#xD;
             intraventricular condition, left or right bundle branch block, AB block of any degree&#xD;
             or QTc prolongation), repolarization (ST segment or T wave) abnormality, significant&#xD;
             atrial or ventricular arrhythmia, frequent atrial or ventricular ectopy (e.g. frequent&#xD;
             premature atrial contractions, 2 premature ventricular contractions in a row), ST&#xD;
             elevation consistent with ischemia, or evidence of past or evolving myocardial&#xD;
             infarction&#xD;
&#xD;
          -  Has history of seizure disorder, immunodeficiency, chronic illness, autoimmune&#xD;
             disease, diabetes mellitus active malignancy or use of immunosuppressive medications.&#xD;
&#xD;
          -  Has evidence of psychiatric, medical and/or substance abuse problems during the past&#xD;
             six months that the investigator believes would adversely affect the volunteer's&#xD;
             ability to participate in the trial.&#xD;
&#xD;
          -  Has occupational or other responsibilities that would prevent completion of&#xD;
             participation in the study.&#xD;
&#xD;
          -  Has received any live attenuated vaccine within 60 days of study entry.&#xD;
&#xD;
          -  Has used experimental therapeutic agents within 30 days of study entry.&#xD;
&#xD;
          -  Has received blood products or immunoglobulins in the past three months.&#xD;
&#xD;
          -  Has history of anaphylaxis or other serious adverse reactions to vaccines.&#xD;
&#xD;
          -  Has previously received an HIV vaccine or an MVA or vaccinia vaccine.&#xD;
&#xD;
          -  Has chronic or active Hepatitis B or Hepatitis C virus infection or active syphilis&#xD;
             (positive RPR and FTA).&#xD;
&#xD;
          -  Has had an immediate type hypersensitivity reaction to eggs, egg products or&#xD;
             neomycin/streptomycin (used to prepare MVA vaccine).&#xD;
&#xD;
          -  Is a study site employee.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary Marovich, MD, DTM&amp;H</last_name>
    <role>Principal Investigator</role>
    <affiliation>US Military HIV Research Program</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>US Military HIV Research Program</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>September 13, 2006</study_first_submitted>
  <study_first_submitted_qc>September 13, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2006</study_first_posted>
  <last_update_submitted>October 13, 2017</last_update_submitted>
  <last_update_submitted_qc>October 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MVA vector</keyword>
  <keyword>Immunogenicity</keyword>
  <keyword>HIV vaccine</keyword>
  <keyword>HIV preventative vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

